Mauna Kea Technologies Shows Positive Clinical Results for Cellvizio in IBS

Mauna Kea Technologies has announced positive clinical data for Cellvizio® during UEG Week 2024, highlighting its role in detecting and treating food intolerance-related gut barrier dysfunction in IBS patients. Conducted in Germany, the study by Prof. Jost Langhorst involved 119 IBS patients screened with Cellvizio® during a food challenge. 62% showed impaired intestinal barrier response. Treatment combined a multimodal approach, including an elimination diet, resulting in a 71% improvement in gut integrity for follow-up patients.

Clinical outcomes showed significant improvements in IBS symptoms and quality of life. Prof. Langhorst noted the study as a forward step in IBS management, asserting Cellvizio®'s capability for real-time assessment and accurate diagnosis of gut dysfunctions. These findings underscore Cellvizio® as a potentially valuable tool for IBS management. Sacha Loiseau, CEO of Mauna Kea Technologies, emphasized the breakthrough for millions seeking solutions to IBS-related symptoms, indicating strong interest from medical professionals and plans to expand CellTolerance® development.